DOT1L and cancer: In undifferentiated pleomorphic bone sarcoma (Ali et al., 2019) and in adrenocorticotropic hormone–independent macronodular adrenocortical hyperplasias (Cao et al., 2014) DOT1L recurrent mutations were identified, highlighting the potential role of deregulated chromatin remodeling pathways also in these cancer types.